Immunotherapy of melanoma: A dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy

Journal of Immunology

Volumn 166, Issue 12, 2001, Pages 7370-7380

  Winter, H ^a   Hu, H M ^a   McClain, K ^a   Urba, W J ^a   Fox, B A ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MONOCLONAL ANTIBODY; PERFORIN; VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DEPIGMENTATION; DRUG EFFICACY; EFFECTOR CELL; FEMALE; GRANULOCYTE; IMMUNITY; KNOCKOUT MOUSE; LUNG METASTASIS; MACROPHAGE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

EID: 0035877073     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.12.7370     Document Type: Article

References (41)

1. - T cells in the antitumor immune response
2. Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Statl
3. Growth control of melanoma cells and melanocytes by cytokines
4. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas
5. Cellular responses to interferon-γ
6. The IFN-γ receptor: A paradigm for cytokine receptor signaling
7. Immunotherapy of a murine tumor with interleukin 2: Increased sensitivity after MHC class I gene transfection
8. Defective presentation of endogenous antigens by a murine sarcoma: Implications for the failure of an anti-tumor immune response
9. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
10. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
11. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
12. Monoclonal antibodies to murine γ-interferon which differentially modulate macrophage activation and antiviral activity
13. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: Comparison of activating cytokines and evidence for independent production
14. + tumor-infiltrating lymphocytes
15. γ-interferon plays a key role in T-cell-induced tumor regression
16. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
17. Type 1 vs type 2 cytokine release by V β T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
18. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
19. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes
20. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L)
21. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes
22. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma
23. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor
24. Transgenic models for the study of prostate cancer
25. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon-γ
26. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy
27. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
28. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor
29. Coupling and uncoupling of tumor immunity and autoimmunity
30. + T cells in the priming and effector/memory phases of adoptive immunotherapy
31. + tumor-draining lymph node cells involved in mediating tumor regression
32. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer
33. + T cell subpopulations in established pulmonary metastases
34. Lymphotoxin αβ is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation
35. Multiple defects of immune cell function in mice with disrupted interferon-γ genes
36. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
37. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors
38. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
39. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics
40. IFN and lymphocytes prevent primary turnout development and shape tumour immunogenicity